Leadership & Innovation in Oncology

Board of Directors

Chairman of the Board

Iain Dukes, PhD

Dr. Dukes previously served as Senior Vice-President and Head of Business Development and Licensing for Merck Research Laboratories through May 2016. He joined Merck in August 2013. Prior to joining Merck, Dr. Dukes was Vice-President of External Research & Development at Amgen, from August 2010 to August 2013. From 2007 to 2010, Dr. Dukes was the President and Chief Executive Officer, and a member of the board of directors, of Essentialis Therapeutics, a clinical stage biotechnology company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases. From 2000 to 2007, Dr. Dukes was Vice President of Scientific and Technology Licensing at GlaxoSmithKline, and prior to that, from 1990 to 1999, he held various positions at Glaxo Wellcome, including Head of Exploratory Development for Metabolic and Urogenital Diseases and Head of Ion Channel Drug Discovery Group. Dr. Dukes holds Master of Jurisprudence and Doctorate of Philosophy degrees from the University of Oxford, a Master of Science degree in Cardiovascular Studies from the University of Leeds, and a Bachelor of Science degree in Pharmacology from the University of Bath.

President & Chief Executive Officer

Maria Fardis, PhD, MBA

Dr. Fardis has extensive experience in drug development and novel cancer treatments. Prior to joining Iovance Biotherapeutics, Dr. Fardis was chief operating officer at Acerta Pharma working on the development of acalabrutinib until the company’s acquisition by AstraZeneca. Before joining Acerta, Dr. Fardis held the position of chief of oncology operations and alliances at Pharmacyclics where she oversaw development of ibrutinib (IMBRUVICA®), abexinostat (HDAC inhibitor), and FVIIa inhibitor programs. She was a key contributor in the creation of a broad clinical program for ibrutinib, as well as NDA and MAA submissions. Previously, Dr. Fardis held a number of key scientific and management roles at Gilead Sciences. At Gilead, she was involved with multiple therapeutic areas including antivirals, oncology, and cardiovascular therapeutics and worked on the development and life cycle management of ambrisentan (Letairis®). She received her PhD in organic chemistry from UC Berkeley and holds an MBA from Golden Gate University.

Director

Ryan Maynard

Mr. Maynard was appointed to the Board of Directors on February 16, 2015. Mr. Maynard currently is the Chief Financial Officer of Blade Therapeutics. He was formerly the Executive Vice President and Chief Financial Officer of Rigel Pharmaceuticals, Inc., a clinical-stage drug development public company until 2017. He joined Rigel in September 2001 as Corporate Controller and was appointed as an Assistant Secretary in October 2001. In June 2006 he became Rigel’s Vice President of Finance and Acting Chief Financial Officer and became its Vice President and Chief Financial Officer in January 2007. Prior to joining Rigel, Mr. Maynard was Corporate Controller and Director of Finance and Accounting for Personify, Inc., an e-commerce software company, from November 1999 to April 2001. From July 1998 to October 1999 he served as Controller of General Magic, Inc. and from July 1994 to June 1998 he held various positions at Siliconix, Inc., most recently as Senior Finance Manager. He previously worked at Ernst & Young, LLP. Mr. Maynard holds a B.S. in Commerce—Accounting from Santa Clara University.

Committees

Audit Committee

Chair

Director

Merrill A. McPeak

General McPeak retired a four-star general after nearly four decades in the US Air Force and served as USAF chief of staff from 1990 to 1994.  A career fighter pilot, General McPeak spent two years with the Air Force’s elite aerobatic team, the Thunderbirds, and flew 269 combat missions during the Vietnam conflict. Senior leadership assignments included command of the 20th Fighter Wing in NATO, the Twelfth Air Force (and concurrently, commander of US Southern Command Air Forces), and the Pacific Air Forces. He was Air Force chief of staff during a period of active US involvement overseas, including Operation Desert Storm.

Following retirement from active service, General McPeak began a second career in business. He is or has been a director of numerous public companies, including Tektronix and TWA.  He is currently a director of Aerojet Rocketdyne, Lilis Energy, Iovance Biotherapeutics, Research Solutions, and Valence Surface Technologies (privately held).

General McPeak was a national co-chairman of Obama for President, and in 2010 the President appointed him to the American Battle Monuments Commission, where he currently serves as chairman.  General McPeak is a distinguished graduate of the San Diego State College ROTC program and received the university’s first ever Lifetime Achievement Award in 1992. He also holds a master’s in international relations from George Washington University.

Committees

Nominating and Corporate Governance Committee

Chair

Audit Committee

Member

Compensation Committee

Member

Director

Wayne Rothbaum

Mr. Rothbaum is currently the President of Quogue Capital LLC, a life sciences investment fund he founded in 2001. Beginning in 2012, Mr. Rothbaum served as the co-founder and largest investor of Acerta Pharma, B.V., a Dutch biotech focused on developing selective, covalent small molecules to treat cancer and inflammation. Acerta Pharma was sold to Astra Zeneca in February 2016. From February 2013 until its sale in February 2016, Mr. Rothbaum served as the executive chairman of Acerta Pharma. From 1993 until 2001, Mr. Rothbaum led the biotechnology practice at the strategic consulting firm The Carson Group. Mr. Rothbaum graduated Phi Beta Kappa from Binghamton University in 1990 with a dual major in political science and psychology and received his Master’s degree in international economics from The George Washington University.

Committees

Compensation Committee

Member

Director

MICHAEL WEISER, M.D., PH.D.,

Dr. Weiser is the founder and currently the co-CEO of Actin Biomed LLC, a healthcare investment firm focused on the discovery and development of novel treatments for unmet medical needs. Prior to joining Actin Biomed, Dr. Weiser was the Director of Research at Paramount BioCapital, a pharmaceutical development and healthcare investment firm.  Dr. Weiser currently serves on the board of directors of Emisphere Technologies, Inc., a pharmaceutical and drug delivery company. Dr. Weiser formerly served as the chairman of the board of directors of Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company that was acquired by H. Lundbeck A/S in 2014 and was on the board of directors of Ziopharm Oncology, Inc., a publicly traded biopharmaceutical company focused on immunotherapies in oncology. Dr. Weiser holds a B.A. in Psychology from the University of Vermont, received his M.D. from New York University School of Medicine, and completed his Ph.D. in Molecular Neurobiology at Cornell University Medical College.

Committees

Compensation Committee

Chair

Audit Committee

Member

Nominating and Corporate Governance Committee

Member